Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium
Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston. Eleven accepted abstracts will be presented to spotlight recent updates to its Pulsed Field Ablation (PFA) and Ultrasound portfolios, underscoring its commitment to evidence‑driven innovation that elevates the standard of care for physicians and patients worldwide.
Building on Johnson & Johnson’s dedication to continuously evolve PFA technologies based on real-world learnings and our scientific expertise, the company is introducing the VARIPULSE Plus Platform. This platform update introduces automated irrigation flow to build procedural confidence and reinforce its well-established safety profile.i,ii The VARIPULSE Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO 3 System.1,iii,iv This combination offers enhanced precision, efficiency, and procedural reproducibility for physicians treating patients with AFib.v,vi,vii
Johnson & Johnson is also announcing the full commercial release of NUVISION NAV Ultrasound Catheter, the world’s first 4D intracardiac imaging catheter fully integrated with a 3D electroanatomical mapping system. Fully integrated with the CARTO 3 System, NUVISION NAV delivers real-time 4D intracardiac imaging designed to enhance anatomical visualization, support precise navigation and guide complex EP proceduresviii,ix with minimal catheter manipulation[2] and reduced fluoroscopy use.x,xi. As a global leader in cardiac imaging and electrophysiology, Johnson & Johnson is redefining the role of intracardiac ultrasound and setting a new standard for imaging-driven EP guidance.
“Evidence-based innovation is the foundation of how we advance arrhythmia care. The data and technology updates we are sharing at AF Symposium demonstrate how we are continuously strengthening our electrophysiology portfolio,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech. “These technology advancements and upcoming iterations are built on our scientific foundation and will continue raising the bar for AFib ablation.”
Highlights of data being presented include:
Late-Breaking Presentation: Pulse Field Ablation with a Large-Tip Focal Catheter with 3D Mapping Integration: Early Outcomes from the Omny-AF Single-Arm Pilot Study. Friday, February 6. 5:30pm ET, Dr. Dinesh Sharma3
Poster Presentation: Reduced Neurovascular Events Following Workflow and Irrigation Adjustments with a Variable Loop PFA Catheter for Ablation of Atrial Fibrillation. AFS2026-57. Dr. Moussa Mansour4
Poster Presentation:Acute Safety Profile of Variable-Loop Circular Catheter Pulsed Field Ablation for Paroxysmal and Persistent Atrial Fibrillation in the REAL AF Registry. AFS2026-35. Dr. Mohammad Ali Jazayeri5
Poster Presentation: The Variable Loop Circular Catheter Safety Survey (VariSure) Early Results. AFS2026-76. Dr. Christopher Porterfield6
Poster Presentation: Irrigation Flow Optimization During Pulsed Field Ablation: Preclinical Insights with a Variable Loop Circular Catheter. AFS2026-102,Dr. Fengwei Zou7
Poster Presentation: 4D Intracardiac Echo with NUVISION™- versus transesophageal echocardiography – guidance for left atrial appendage occlusion. AFS2026-97. Dr. David Weisman8
In addition to data presentations, will support a variety of educational programs, in-booth presentations and training opportunities for attendees. Experts will lead hands-on sessions powered by CARTO 3 System, the world’s leading cardiac mapping system.9 Participants will be able to experience the VARIPULSE Plus Platform’s new automated irrigation-flow control in addition to the next-generation NUVISION NAV Ultrasound Catheter in a simulation for concomitant procedures.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke.
Source Link: https://www.jnj.com/
